Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 80 of 6351
-
New trial tests which immunotherapy combo best battles melanoma before surgery
Disease control Recruiting nowAt present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NE…
Phase 3 • Sponsor: Hildur Helgadottir • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from startin…
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New gene therapy combo aims to boost ovarian cancer survival
Disease control Recruiting nowThis is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Phase 3 • Sponsor: Imunon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for kids with rare epilepsy: drug trial targets seizure control
Disease control OngoingA Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
Phase 3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Balloon catheter aims to supercharge CPR and save more lives
Disease control Recruiting nowThe NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, tempora…
Sponsor: neurescue • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Supercharged immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific combination mutated KRAS and HLA, activating the T cells …
Phase 1/2 • Sponsor: Anocca AB • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
After stroke, a balloon or a stent? trial tests which rescue opens blocked brain arteries better
Disease control Recruiting nowThe ANGEL-ICAS trial is a multicenter, prospective, randomized, open-label, blinded-endpoint study designed to determine whether rescue balloon angioplasty is noninferior to rescue stenting in patients with intracranial atherosclerosis-related acute ischemic stroke who have resid…
Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug aims to cut deaths and heart crises in rare amyloidosis
Disease control Recruiting nowThe purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the …
Phase 3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Zapping the brain to save memory: a new hope for Alzheimer's?
Disease control Recruiting nowThe goal of this clinical trial is to learn if personalized, multimodal imaging-guided, EEG-based closed-loop Temporal Interference Brain Stimulation (TIBS) can improve memory function in individuals with preclinical Alzheimer's Disease (AD). The main questions it aims to answer…
Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can supercharged immune cells stop leukemia from returning?
Disease control Recruiting nowThis is an investigator-initiated clinical trial evaluating the safety and efficacy of allogeneic γδ T cell infusion for relapse prevention in high-risk acute myeloid leukemia patients after transplantation.
Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a targeted radiation combo boost rectal cancer remission?
Disease control PausedThe purpose of this study is to explore the efficacy and safety of involved-field radiotherapy-TNT combined with PD-1 inhibitors in pMMR locally advanced rectal cancer.
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowResearchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the b…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill hopes to tame rare childhood brain diseases
Disease control Recruiting nowAn 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangl…
Phase 3 • Sponsor: Azafaros B.V. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New sudan ebola vaccine moves to phase 2 trial in healthy adults
Vaccine OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Phase 2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: Vaccine
Last updated Jun 27, 2026 09:03 UTC
-
Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
Disease control OngoingExploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a new drug cut heart failure hospitalizations in people with obesity?
Disease control Recruiting nowThis trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with pres…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Fetal balloon surgery may boost survival in severe birth defect
Disease control Recruiting nowThis registry study aims to confirm that FETO increases neonatal survival to discharge and reduces long-term morbidity in fetuses with isolated left CDH and o/e LHR \< 30%, or isolated right CDH and o/e LHR ≤ 45%, compared to those receiving standard care. This prospective regist…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Mpox vaccine trial for pregnant women launches in congo
Vaccine OngoingThis Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be c…
Phase 3 • Sponsor: Jean-Pierre Van geertruyden • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
Can starting treatment right after a first attack prevent relapses in children?
Disease control Recruiting nowAmong all non viral encephalitis, myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) are the second most frequent diagnosis in children. Risk of relapses varies according to studied cohorts and cognitive and academic difficulties are more and more detected …
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New weekly shot could help diabetics shed pounds
Disease control OngoingThis is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obe…
Phase 3 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC